226 related articles for article (PubMed ID: 25399762)
1. Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).
Carradori S; Petzer JP
Expert Opin Ther Pat; 2015 Jan; 25(1):91-110. PubMed ID: 25399762
[TBL] [Abstract][Full Text] [Related]
2. MAO inhibitors and their wider applications: a patent review.
Carradori S; Secci D; Petzer JP
Expert Opin Ther Pat; 2018 Mar; 28(3):211-226. PubMed ID: 29324067
[TBL] [Abstract][Full Text] [Related]
3. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential.
Carradori S; Secci D; Bolasco A; Chimenti P; D'Ascenzio M
Expert Opin Ther Pat; 2012 Jul; 22(7):759-801. PubMed ID: 22702491
[TBL] [Abstract][Full Text] [Related]
4. An updated patent review on monoamine oxidase (MAO) inhibitors.
Guglielmi P; Carradori S; D'Agostino I; Campestre C; Petzer JP
Expert Opin Ther Pat; 2022 Aug; 32(8):849-883. PubMed ID: 35638744
[TBL] [Abstract][Full Text] [Related]
5. Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders.
Dhiman P; Malik N; Sobarzo-Sánchez E; Uriarte E; Khatkar A
Molecules; 2019 Jan; 24(3):. PubMed ID: 30678358
[TBL] [Abstract][Full Text] [Related]
6. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
7. Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Tripathi AC; Upadhyay S; Paliwal S; Saraf SK
Eur J Med Chem; 2018 Feb; 145():445-497. PubMed ID: 29335210
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
Patil PO; Bari SB; Firke SD; Deshmukh PK; Donda ST; Patil DA
Bioorg Med Chem; 2013 May; 21(9):2434-50. PubMed ID: 23517722
[TBL] [Abstract][Full Text] [Related]
9. Focusing on new monoamine oxidase inhibitors.
Bolasco A; Carradori S; Fioravanti R
Expert Opin Ther Pat; 2010 Jul; 20(7):909-39. PubMed ID: 20553094
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
11. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
Binda C; Milczek EM; Bonivento D; Wang J; Mattevi A; Edmondson DE
Curr Top Med Chem; 2011 Nov; 11(22):2788-96. PubMed ID: 22039878
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
[TBL] [Abstract][Full Text] [Related]
13. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
14. An update on amine oxidase inhibitors: multifaceted drugs.
Song MS; Matveychuk D; MacKenzie EM; Duchcherer M; Mousseau DD; Baker GB
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():118-24. PubMed ID: 23410524
[TBL] [Abstract][Full Text] [Related]
15. A scaffold hopping approach to identify novel monoamine oxidase B inhibitors.
Geldenhuys WJ; Funk MO; Van der Schyf CJ; Carroll RT
Bioorg Med Chem Lett; 2012 Feb; 22(3):1380-3. PubMed ID: 22225638
[TBL] [Abstract][Full Text] [Related]
16. Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors.
Pisani L; Catto M; Nicolotti O; Grossi G; Di Braccio M; Soto-Otero R; Mendez-Alvarez E; Stefanachi A; Gadaleta D; Carotti A
Eur J Med Chem; 2013; 70():723-39. PubMed ID: 24231308
[TBL] [Abstract][Full Text] [Related]
17. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
Kumar B; Gupta VP; Kumar V
Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
19. Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors.
Pisani L; Barletta M; Soto-Otero R; Nicolotti O; Mendez-Alvarez E; Catto M; Introcaso A; Stefanachi A; Cellamare S; Altomare C; Carotti A
J Med Chem; 2013 Mar; 56(6):2651-64. PubMed ID: 23437843
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
